Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.76 USD | +5.40% | +7.25% | +6.90% |
Financials (USD)
Sales 2024 * | 43.3M | Sales 2025 * | 165M | Capitalization | 571M |
---|---|---|---|---|---|
Net income 2024 * | -261M | Net income 2025 * | -220M | EV / Sales 2024 * | 8.69 x |
Net cash position 2024 * | 195M | Net cash position 2025 * | 89.8M | EV / Sales 2025 * | 2.92 x |
P/E ratio 2024 * |
-2.24
x | P/E ratio 2025 * |
-2.93
x | Employees | 452 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.33% |
Latest transcript on Phathom Pharmaceuticals, Inc.
1 day | +5.40% | ||
1 week | +7.25% | ||
Current month | +8.08% | ||
1 month | -0.41% | ||
3 months | +41.04% | ||
6 months | +22.31% | ||
Current year | +6.90% |
Managers | Title | Age | Since |
---|---|---|---|
Azmi Nabulsi
FOU | Founder | 64 | 18-01-08 |
Terrie Curran
CEO | Chief Executive Officer | 55 | 19-07-31 |
David Socks
FOU | Founder | 49 | 18-01-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Heidi Fields
BRD | Director/Board Member | 69 | 19-09-26 |
Frank Karbe
BRD | Director/Board Member | 56 | 22-04-24 |
Michael Cola
CHM | Chairman | 64 | 19-09-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.02% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 9.76 | +5.40% | 1,082,510 |
24-05-01 | 9.26 | +2.55% | 512,297 |
24-04-30 | 9.03 | -3.42% | 414,106 |
24-04-29 | 9.35 | +1.85% | 431,026 |
24-04-26 | 9.18 | +0.88% | 370,890 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.90% | 571M | |
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+46.68% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |
- Stock Market
- Equities
- PHAT Stock